[HTML][HTML] Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial
EJ Lenze, C Mattar, CF Zorumski, A Stevens… - Jama, 2020 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of
an excessive immune response. Fluvoxamine may prevent clinical deterioration by
stimulating the σ-1 receptor, which regulates cytokine production. Objective To determine
whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and
decreases the severity of disease. Design, Setting, and Participants Double-blind,
randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants …
an excessive immune response. Fluvoxamine may prevent clinical deterioration by
stimulating the σ-1 receptor, which regulates cytokine production. Objective To determine
whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and
decreases the severity of disease. Design, Setting, and Participants Double-blind,
randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants …
以上显示的是最相近的搜索结果。 查看全部搜索结果